Avastin.net

Inhibition of new and recurrent vessel growth provides continued disease control

In a phase III study in mCRC, prolonged inhibition of vessel regrowth by Avastin produced significant increases in OS independent of tumour response²⁶

Reprinted with permission. © 2009 American Society of Clinical Oncology. All rights reserved. Grothey A, et al: J Clin Oncol 26(2), 2008:183–9.

• Although existing vasculature is essential for tumour survival, tumours are unable to grow and spread without the generation of new vasculature.¹
• Inhibition of neovascularisation by Avastin inhibits the growth of the tumour and prevents metastasis
  • in clinical trials, patient survival is extended and PD is delayed.^17–22,24
• Restriction of tumour growth means that more patients experience stable disease
  • in the AVADO phase III study in mBC, the proportion of patients with PD as best response decreased from 12% in the placebo arm to 4% in the Avastin 15mg/kg arm.²⁵
• Sustained control of tumour growth by Avastin can translate into clinical benefit regardless of patients’ objective response to therapy
  • in a phase III trial in CRC, objective response did not predict the magnitude of PFS or OS benefit achieved following the addition of Avastin to chemotherapy; significant increases in both PFS and OS were reported in patients with complete/partial response, stable disease or no response, alike.²⁶